PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton Box}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bimacure 500mg Intrauterine Suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Each 19 g polyethylene syringe contains an oily suspension of 500 mg Cephapirin (as cephapirin benzathine).

3. PACKAGE SIZE

10 syringes.

4. TARGET SPECIES

Cows.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Intrauterine use.

7. WITHDRAWAL PERIODS

Withdrawal period:

Meat and offal: 1 day.
Milk: Zero hours.

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Syringes are for single use only.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Bimeda Animal Health Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 50146/4045

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {Label}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bimacure

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

500 mg cefapirin (as cefapirin benzathine).

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Bimacure 500mg Intrauterine Suspension for Cattle.

2. Composition

Syringe containing a suspension of 500 mg cefapirin (as Cefapirin benzathine) in an oily base**.**

3. Target species

Cows.

4. Indications for use

For the treatment of subacute and chronic endometritis in cows (at least 14 days after parturition) caused by bacteria susceptible to cefapirin.

5. Contraindications

Do not use in animals with known hypersensitivity to cephalosporins or to any of the excipients.

6. Special warnings

Special warnings:
None.

Special precautions for safe use in the target species:
Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefapirin and may decrease the effectiveness of the treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Penicillin and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross reactions to cephalosporins and *vice versa*.
Allergic reactions to these substances are occasionally serious.

1. Do not handle this veterinary medicinal product if you know you are sensitised or if you have been advised not to work with such preparations.
2. Handle this veterinary medicinal product with great care to avoid exposure, taking all recommended precautions.
3. If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.

Personal protective equipment consisting of protective gloves should be worn when handling the veterinary medicinal product.
Accidental spillage on the skin should be washed off immediately with soap and water.
Wash hands after use.

FOR ANIMAL TREATMENT ONLY.

Pregnancy and lactation:
The use is not recommended during pregnancy.
Can be used during lactation.

Interaction with other medicinal products and other forms of interaction:
Not to be administered concurrently with other intrauterine antibiotic preparations.

Overdose:
The veterinary medicinal product is supplied as a single dose syringe therefore overdose is unlikely to occur.

7. Adverse events

Cattle (cows):

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Allergic reaction

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian.

You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

For intrauterine use.

The contents of one syringe of the veterinary medicinal product, corresponding to 500 mg of cefapirin (as cefapirin benzathine) should be introduced into the lumen of the uterus using the disposable catheter provided as follows:

1. Shake syringe before use.
2. Fix the syringe to the catheter.
3. Take the cervix of the uterus into one gloved hand introduced into the rectum
4. Introduce the catheter through the cervix into the lumen of the uterus, by gentle oscillating movements of the cervix.
5. Inject the contents of the syringe into the uterus.

Depending on the response, a second treatment 7 - 14 days later may be required in some cases if clinical signs persist.
In animals that have been inseminated, the veterinary medicinal product may be used one day after insemination. In cases of pyometra, pre-treatment with prostaglandin is recommended in order to induce luteolysis and remove debris from the uterine cavity.

9. Advice on correct administration

See section ‘Dosage for each species, routes and method of administration’.

10. Withdrawal periods

Meat and offal: 1 day.
Milk: Zero hours.

11. Special storage precautions

Keep out of the sight and reach of children.
Syringes are for single use only.
This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 50146/4045

Low linear density polyethylene syringe barrel with low density polyethylene plunger and cap containing 19g of oily suspension, packed in boxes of 10 syringes. Intrauterine catheters are provided for administration.

Pack sizes:
Cardboard box with 10 x 19 g syringes and 10 intrauterine catheters.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:
Bimeda Animal Health Limited
2/3/4 Airton Close
Tallaght
Dublin 24
Ireland

Manufacturer responsible for batch release:
Dopharma France S.A.S,
23 rue du Prieuré,
Saint-Herblon,
44150 Vair Sur Loire,
France.

Local representatives and contact details to report suspected adverse reactions:
For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder listed below.

Cross Vetpharm Group UK Limited (Trading as Bimeda)
Unit 2, Bryn Cefni Industrial Park
Llangefni, LL77 7XA
United Kingdom
Tel: 01248 725 400

17. Other information

POM-V

Gavin Hall
Approved: 19 May 2026